Venus Remedies Bags Marketing Nod For Docetaxel From Israel

Venus Remedies has obtained Israeli commercial authorization for docetaxel and Colombian marketing authorization for cytarabine. While docetaxel, an antineoplastic drug, is effective in the treatment of breast, prostate, head and neck, and non-small cell lung cancer, cytarabine is effective in the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukaemia, and chronic myelocytic leukaemia.

Israel's pharmaceutical market, valued at about $5 billion, is projected to grow at a five-year compound annual growth rate (CAGR) of 4.2 per cent up to 2026. Israel has a dynamic pharmaceutical expanse known for its innovation and commitment to healthcare excellence. The marketing authorisation for cytarabine from Colombia, on the other hand, marks a significant expansion of Venus Remedies in the Latin American market, as per pharmabiz.

Colombia, the third-largest pharmaceutical market in South America, is expected to develop at a five-year CAGR of 3.1% through 2026, and has emerged as an important player in the pharmaceutical sector, demonstrating solid growth and encouraging innovation. The Colombian market for oncology medications has been steadily expanding.

Saransh Chaudhary, CEO, Venus Medicine Research Centre (VMRC), said, “We are excited about the prospect of bringing these advanced therapies to patients in Israel and Colombia, and we remain committed to exploring new frontiers in healthcare that align with our vision of a healthier world,” he said.

Aditi K Chaudhary, President, International Business, Venus Remedies, said, “These marketing approvals mark a significant stride in our global mission to enhance healthcare accessibility. One of the largest exporters of docetaxel, Venus Remedies is proud to include Israel in the list of countries it supplies docetaxel to, including Malaysia, Namibia, Myanmar, Panama, Indonesia, Iraq, Tanzania, Germany, and Zimbabwe. Likewise, the market reach of Venus Remedies for cytarabine extends to Guinea-Bissau, Jordan, Namibia, Oman, Saudi Arabia, Tunisia and Venezuela, besides Colombia."